Format

Send to

Choose Destination
Eur J Gynaecol Oncol. 2007;28(2):103-8.

Tumour M2-PK as a predictor of surgical outcome in ovarian cancer, a prospective cohort study.

Author information

1
South East London Cancer Network, Gynae-Oncology Department, Guy's and St Thomas', and King's College Hospitals, London.

Abstract

BACKGROUND:

Optimal cytoreduction is a major prognostic factor in ovarian cancer; several clinical, radiological and biochemical predictors have been studied. Tumour M2-PK (TU M2-PK) is over-expressed in tumour cells and can be detected in plasma samples but its role in ovarian cancer has not yet been evaluated.

OBJECTIVES:

To assess the potential clinical applications of TU M2-PK in ovarian cancer particularly in relation to surgical cytoreduction.

SETTINGS:

The Gynaecological Cancer Centre at both King's College and St Thomas' Hospitals; London; UK.

METHODS:

Patients with suspected ovarian cancer were recruited prospectively during the years 2004-2005. Blood samples were collected before surgery for plasma TU M2-PK assays. Data were analysed in relation to cancer diagnosis and outcome. Statistical analysis was performed using Analyse-It' and SPSS' V13.

RESULTS:

100 patients were recruited; 52 diagnosed with invasive ovarian cancer, 13 with borderline tumours and 35 patients had benign conditions. The mean M2-PK concentration in cancer patients was 52 U/ml vs 31 U/ml in patients with borderline tumours and 22 U/ml in those with benign conditions (p < 0.001); it was significantly raised in association with late stage disease and higher grade (p < 0.05). Taking 35 U/ml as a reference point, TU M2-PK predicted sub-optimal cytoreduction in advanced stage disease with a sensitivity of 69%, specificity of 60% and overall efficacy of 61% (95% CI: 44-75%).

CONCLUSION:

TU M2-PK was significantly raised in ovarian cancer patients, particularly those with higher stage disease. The potential clinical application as a predictor of surgical outcome in ovarian cancer needs further evaluation.

PMID:
17479670
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center